

Minerva Neurosciences, Inc.  
Form 8-K  
May 15, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 15, 2017**

**Minerva Neurosciences, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36517**  
**(Commission**  
  
**File Number)**

**26-0784194**  
**(I.R.S. Employer**  
  
**Identification No.)**

**1601 Trapelo Road**

**Suite 284**

**Waltham, MA**

**(Address of principal executive offices)**

**02451**

**(Zip Code)**

**(Registrant's telephone number, including area code): (617) 600-7373**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events**

On May 15, 2017, Minerva Neurosciences, Inc. (the Company ) issued a press release providing details of the Company s MIN-101 end-of-Phase 2 meeting with the U.S. Food and Drug Administration, and a press release providing an update on the Company s MIN-101 Phase 3 design and development strategy. A copy of the above referenced press releases are filed as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K.

The Company is also filing the investor presentation slides attached as Exhibit 99.3 to this Current Report on Form 8-K which the Company may use from time to time with investors and analysts. The presentation will also be available in the investor relations section of the Company s website.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press Release of the Company dated May 15, 2017
99.2	Press Release of the Company dated May 15, 2017
99.3	Presentation of the Company dated May 16, 2017

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MINERVA NEUROSCIENCES, INC.**

By: /s/ Mark S. Levine  
Name: Mark S. Levine  
Title: Senior Vice President, General  
Counsel and Secretary

Date: May 15, 2017

**INDEX OF EXHIBITS**

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press Release of the Company dated May 15, 2017
99.2	Press Release of the Company dated May 15, 2017
99.3	Presentation of the Company dated May 16, 2017